As of October 2, 2024, the U.S. Food and Drug Administration (FDA) has announced that the Tirzepatide shortage has been resolved. This means that all doses of Eli Lilly’s Tirzepatide weight-loss drug (Zepbound) and its diabetes drug (Mounjaro) have been removed from the Drug Shortage List and generally are available for patients. This update follows our recent article, Tirzepatide and Semaglutide Still on the Drug Shortage List, which highlighted the challenges surrounding the availability of these medications. According to the FDA, while the national shortage has been resolved, patients may still experience localized shortages due to distribution issues.
This update is in contrast to the ongoing shortage of semaglutide (Ozempic and Wegovy). While the availability of Tirzepatide is improving, health care professionals should remain aware of the challenges posed by localized supply issues and continue monitoring the status of other medications still on the shortage list.
Providers offering weight loss management services and those prescribing these medications should continue communicating with patients about potential delays and ensure they remain compliant with both state and federal regulations related to telehealth, prescriptions, and compounded drugs.
Navigate Compliance with ByrdAdatto
Staying up to date with ever-changing regulations is key to a successful practice. At ByrdAdatto, we provide the insights you need to remain informed and compliant. To learn how this alert impacts your practice, contact ByrdAdatto.
